Annons
Xspray Pharma logotypXspray Pharma
17 november 2026 kl. 12:15(MFN)

Subscription period in Xspray Pharma’s rights issue starts today

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.

The subscription period in Xspray Pharma AB’s (publ) rights issue, announced on 6 November, starts today. The subscription period runs up to and including 1 December 2026. Trading in subscription rights runs from today up to and including 26 November.

Shareholders who held shares in Xspray Pharma on the record date of 13 November have received one subscription right for each share held. Five subscription rights entitle the holder to subscribe for one new share at SEK 9.50 during the subscription period.

The subscription period runs up to and including 1 December, but banks and securities institutions may apply earlier deadlines for subscribing for shares. Shareholders therefore need to check the deadlines applied by their bank or securities institution.

Those who do not wish to exercise their subscription rights to subscribe for new shares may instead sell them during the trading period. To avoid losing the value of the subscription rights, holders need either to exercise them or sell them within the respective deadlines. Unexercised subscription rights expire without value and without compensation to the holder.

Full information about the rights issue is available on Xspray Pharma’s website under Rights Issue November 2026.

Källa: MFNMFN
Annons

0 kommentarer

Kommentera nyheten

När du kommenterar ett pressmeddelande publiceras din kommentar även i en speglad tråd under Börssnack så att alla i forumet kan delta i diskussionen!

Logga in eller skapa ett gratis konto för att kommentera nyheten!